Table 1.

Resume of collected data

Demographic data
Number of patients; number of eyes	n = 11 patients; n = 12 eyes
Gender	5 female (45.5%); 6 male (54.5%)
Age of diagnosis	23.0 years (21.25; 29.75)
Age of onset of symptomatic disease	30 years (22.75; 35.0)
Age of liver transplant	34.50 years (27.25; 36.75)
Period between AGV implantation and TSCPC	1.63 years (1.0; 3.65)
Age of TSCPC	49.50 years (43.0; 55.75)
Other ocular manifestations
Scalloped iris	n = 4 (33.3%)
Amyloid deposition on AL capsule	n = 1 (8.3%)
Vitreous amyloidosis/previous PPV	n = 9 (75.0%)
Retinal amyloid angiopathy	n = 7 (58.3%)
AGV implantation
AGV implantation alone/combined with phacoemulsification	n = 8 (66.7%); n = 4 (33.3%)
Tube placement	AC: n = 11 (91.7%); PC: n = 1 (8.3%)
	Replacement from AC to PC: n = 2 (16.7%)
Surgical complications	Hypertensive phase: n = 9 (75.0%)
	Hypotony with athalamia: n = 1 (8.3%)
	Cystic bleb: n = 1 (8.3%)
Previous glaucoma surgeries	Trabeculectomy: n = 2 (16.7%)
Phakic status	Pseudophakic: n = 3 (25.0%)
	Phakic: n = 9 (75.0%)
Transscleral cyclophotocoagulation after AGV
IOP (mm Hg) (mean ± SD)	Baseline: 24.33 ± 4.76
	Last visit: 11.33 ± 2.90
Number of antiglaucomatous medications (mean ± SD)	Baseline: 3.92 ± 0.29
	Last visit: 1.25 ± 1.42
LogMAR BCVA (mean ± SD)	Baseline: 0.34 ± 0.19
	Last visit: 0.39 ± 0.30

AGV, Ahmed glaucoma valve; TSCPC, transscleral cyclophotocoagulation; AL, anterior lens; AC, anterior chamber; PC, posterior chamber; SD, standard deviation